Partnering with the NCI: How to Access Therapeutic Development and Moonshot Resources
The Chester F. Carlson Patent & Trademark Center, in conjunction with the Breast Cancer Coalition of Rochester, the UR Medicine Wilmot Cancer Institute, the Pluta Cancer Center Foundation, the Rochester Regional Health Lipson Cancer Institute, and the Friends & Foundation of the Rochester Public Library are hosting this informative and engaging event.
6 to 7 p.m. - Networking and cocktails are from 6 to 7 p.m.,
7 to 8 p.m. - Lecture
8 to 8:30 p.m. - Q& A
- Thursday, June 14, 2018
- 6:00pm - 8:30pm
- Central - Harold Hacker Hall
- Central Library
The speaker, Jason Cristofaro, PhD, JD, is an intellectual property attorney with the National Cancer Institute (NCI). Dr. Cristofaro’s work has focused on implementing intellectual property policy to the development of novel anticancer therapeutic agents, with a particular focus on enabling innovative public-private partnerships.
Dr. Cristofaro joined NCI’s Division of Cancer Treatment and Diagnosis (DCTD) in 2007 after completing a two-year Presidential Management Fellowship. During his tenure, Dr. Cristofaro’s work has focused on implementing intellectual property policy to support DCTD’s core function of advancing the development of novel anticancer therapeutic agents, with a particular focus on enabling innovative public-private partnerships. Major projects have included revising the division’s policy for managing internal Cooperative Research and Development Agreements (CRADAs), developing a consistent standard for determining monetary contributions of CRADA partners, revising and implementing DCTD contractual agreements for screening potential anticancer compounds, revising the Intellectual Property Option of the Cancer Therapy Evaluation Program, and developing and vetting the overall contractual agreement structures for the NCI Experimental Therapeutics program (NExT), the MATCH initiative and the NCI formulary. Dr. Cristofaro currently serves as Intellectual Property Program Manager for the DCTD and as Alternate Technology Development Coordinator for the NCI. He received his Ph.D. in Microbiology from the University of Maryland and his J.D. from Georgetown University.